Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats

Physiological Research

Volumn 62, Issue SUPPL 1, 2013, Pages

  Hrenak J ^a   Arendasova K ^a   Rajkovicova R ^a   Aziriova S ^a   Repova K ^a   Krajcirovicova K ^a   Celec, P ^a   Kamodyova N ^a   Barta A ^b,e   Adamcova M ^c   Paulis, L ^a   Simko F ^a,d,e  

^a Bratislava   (Slovakia)

^b Inst of Norm and Pathol Physiol   (Slovakia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^e Center of Excellence NOREG   (Slovakia)

Author keywords

C21 substance; Captopril; Doxorubicin; Melatonin; Nephroprotection; Olmesartan; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANTIOXIDANT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IMIDAZOLE DERIVATIVE; MELATONIN; OLMESARTAN; REACTIVE OXYGEN METABOLITE; TETRAZOLE DERIVATIVE; URINARY TRACT AGENT;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; GLOMERULUS FILTRATION RATE; MALE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; TREATMENT OUTCOME; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; CAPTOPRIL; DOXORUBICIN; GLOMERULAR FILTRATION RATE; IMIDAZOLES; MALE; MELATONIN; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 2; RENAL AGENTS; RENAL INSUFFICIENCY, CHRONIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 84891658499     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ABRAHAM P, KOLLI VK, RABI S: Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem Funct 28: 426-433, 2010.
2. AGAPITO MT, ANTOLIN Y, DEL BRIO MT, LOPEZ-BURILLO S, PABLOS MI, RECIO JM: Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res 31: 23-30, 2001.
3. BEHULIAK M, PALFFY R, GARDLIK R, HODOSY J, HALCAK L, CELEC P: Variability of thiobarbituric acid reacting substances in saliva. Dis Markers 26: 49-53, 2009.
4. BENZIE IF, STRAIN JJ: The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 239: 70-76, 1996.
5. CHANG EJ, MUN KC: Effect of melatonin on the malondialdehyde level of neutrophils in cyclosporine-treated rats. Transplant Proc 36: 2165-2166, 2004.
6. COLAK MC, PARLAKPINAR H, TASDEMIR S, SAMDANCI E, KOSE E, POLAT A, SARIHAN E, ACET A: Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Hum Exp Toxicol 31: 945-954, 2012.
7. DOMINGUEZ-RODRIGUEZ A, ABREU-GONZALEZ P, SANCHEZ-SANCHEZ JJ, KASKI JC, REITER RJ: Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 49: 14-22, 2010.
8. DZIEGIEL P, SUDER E, SUROWIAK P, JETHON Z, RABCZYNSKI J, JANUSZEWSKA L, SOPEL M, ZABEL M: Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J Pineal Res 33: 95-100, 2002.
9. EREL O: A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37: 277-285, 2004.
10. GHEORGHIADE M, PANG PS: Acute heart failure syndromes. J Am Coll Cardiol 53: 557-573, 2009.
11. JIRKOVSKY E, POPELOVÁ O, KRIVAKOVÁ-STANKOVA P, VÁVROVA A, HROCH M, HASKOVA P, BRCAKOVÁ-DOLEZELOVA E, MICUDA S, ADAMCOVA M, SIMUNEK T, CERVINKOVA Z, GERSL V, STERBA M: Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther 343: 468-478, 2012.
12. KASCHINA E, GRZESIAK A, LI J, FORYST-LUDWIG A, TIMM M, ROMPE F, SOMMERFELD M, KEMNITZ UR, CURATO C, NAMSOLLECK P, TSCHOPE C, HALLBERG A, ALTERMAN M, HUCKO T, PAETSCH I, DIETRICH T, SCHNACKENBURG B, GRAF K, DAHLOF B, KINTSCHER U, UNGER T, STECKELINGS UM: Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532, 2008.
13. KOCH BC, NAGTEGAAL JE, HAGEN EC, VAN DER WESTERLAKEN MM, BORINGA JB, KERKHOF GA, TER WEE PM: The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled, cross-over study (EMSCAP study). Br J Clin Pharmacol 67: 68-75, 2009.
14. KOCH BC, VAN DER PUTTEN K, VAN SOMEREN EJ, WIELDERS JP, TER WEE PM, NAGTEGAAL JE, GAILLARD CA: Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrol Dial Transplant 25: 513-519, 2010a.
15. KOCH BC, NAGTEGAAL JE, HAGEN EC, TER WEE PM, KERKHOF GA: Different melatonin rhythms and sleepwake rhythms in patients on peritoneal dialysis, daytime hemodialysis and nocturnal hemodialysis. Sleep Med 11: 242-246, 2010b.
16. LEE IC, KIM SH, LEE SM, BAEK HS, MOON C, KIM SH, PARK SC, KIM HC, KIM JC: Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats. Arch Toxicol 86: 1527-1536, 2012.
17. LEE VW, HARRIS DC: Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology 16: 30-38, 2011.
18. MAIONE A, NAVANEETHAN SD, GRAZIANO G, MITCHELL R, JOHNSON D, MANN JF, GAO P, CRAIG JC, TOGNONI G, PERKOVIC V, NICOLUCCI A, DE COSMO S, SASSO A, LAMACCHIA O, CIGNARELLI M, MANFREDA VM, GENTILE G, STRIPPOLI GF: Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 26: 2827-2847, 2011.
19. MATAVELLI LC, HUANG J, SIRAGY HM: Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 57: 308-313, 2011.
20. MONTILLA P, TUNEZ I, MUNOZ MC, LOPEZ A, SORIA JV: Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron 76: 345-350, 1997.
21. MUNCH G, KEIS R, WESSELS A, RIEDERER P, BAHNER U, HEIDLAND A, NIWA T, LEMKE HD, SCHINZEL R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35: 669-677, 1997.
22. NAMSOLLECK P, BOATO F, SCHWENGEL K, PAULIS L, MATHO KS, GEURTS N, THONE-REINEKE C, LUCHT K, SEIDEL K, HALLBERG A, DAHLÖF B, UNGER T, HENDRIX S, STECKELINGS UM: AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis 51: 177-191, 2013.
23. OZ E, ILHAN MN: Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem 286: 11-15, 2006.
24. PAULIS L, SIMKO F: Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 56: 671-684, 2007.
25. PAULIS L, BECKER ST, LUCHT K, SCHWENGEL K, SLAVIC S, KASCHINA E, THöNE-REINEKE C, DAHLöF B, BAULMANN J, UNGER T, STECKELINGS UM: Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 59: 485-492, 2012.
26. PECHANOVA O, MATUSKOVA J, CAPIKOVA D, JENDEKOVA L, PAULIS L, SIMKO F: Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats. Kidney Int 70: 170-176, 2006.
27. RASHIKH A, PILLAI KK, AHMAD SJ, AKHTAR M, NAJMI AK: Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. J Renin Angiotensin Aldosterone Syst 14: 14-22, 2013.
28. REDDY GK, ENWEMEKA CS: A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29: 225-229, 1996.
29. REHMAN A, LEIBOWITZ A, YAMAMOTO N, RAUTUREAU Y, PARADIS P, SCHIFFRIN EL: Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59: 291-299, 2012.